Опыт лечения постковидных когнитивных нарушений (клиническое наблюдение)

Постковидные когнитивные нарушения, в т. ч. у молодого населения, представляют актуальную медико-социальную проблему. Известно, что COVID-19 даже при отсутствии прямого повреждения мозга, связанного с COVID-19-ассоциированным инсультом или энцефалитом, и независимо от тяжести течения инфекции острого периода и возраста пациентов, может вызывать продолжительное и дезадаптирующее когнитивное расстройство. Патогенез этих нарушений сложен, на сегодняшний день до конца не ясен и продолжает активно изучаться. Отсутствуют также стандартизированные диагностические и  лечебные подходы к  ведению пациентов с  постковидными когнитивными нарушениями. Приведенное клиническое наблюдение демонстрирует опыт лечения когнитивных нарушений после COVID-19 у молодого пациента с использованием имеющихся знаний о патогенезе. Проведен обзор современных публикаций по проблеме постковидных когнитивных нарушений. На  основании имеющихся литературных данных обсуждена роль различных патогенетических факторов развития постковидных когнитивных нарушений у представленного пациента. На конкретном клиническом примере дано обоснование выбора лечебных стратегий и необходимости проведения дальнейших исследований в области постковидного синдрома и  его патогенеза, диагностики и  лечения постковидных когнитивных нарушений, что позволит создать доказательную базу для разработки клинических рекомендаций.

1. Alemanno F., Houdayer E., Parma A., Spina A., Del Forno A., Scatolini A. et al. COVID-19 cognitive deficits after respiratory assistance in the subacute phase: A COVID-rehabilitation unit experience. PLoS ONE. 2021;16(2):e0246590. https://doi.org/10.1371/journal.pone.0246590.

2. Daroische R., Hemminghyth M.S., Eilertsen T.H., Breitve M.H., Chwiszczuk L.J. Cognitive Impairment After COVID-19 – A Review on Objective Test Data. Front Neurol. 2021:12:699582. https://doi.org/10.3389/fneur.2021.699582.

3. Altuna M., Sánchez-Saudinós M.B., Lleó A. Cognitive symptoms after COVID-19. Neurol Perspect. 2021:1(Suppl_1):S16–S24. https://doi.org/10.1016/j.neurop.2021.10.005.

4. Henneghan A.M., Lewis K.A., Gill E., Kesler S.R. Cognitive Impairment in Non-critical, Mild-to-Moderate COVID-19 Survivors. Front Psychol. 2022:13:770459. https://doi.org/10.3389/fpsyg.2022.770459.

5. Hampshire A., Trendera W., Chamberlain S.R., Jollya A.E., Grant J.E., Patricke F. et al. Cognitive deficits in people who have recovered from COVID-19. EClinicalMedicine. 2021:39:101044. https://doi.org/10.1016/j.eclinm.2021.101044.

6. Heneka M.T., Golenbock D., Latz E., Morgan D., Brown R. Immediate and long-term consequences of COVID-19 infections for the development of neurological disease. Alzheimers Res Ther. 2020:12(1):69. https://doi.org/10.1186/s13195-020-00640-3.

7. Miskowiak K.W., Johnsen S., Sattler S.M., Nielsen S., Kunalanc K., Rungby J. et al. Cognitive impairments four months after COVID-19 hospital discharge: Pattern, severity and association with illness variables. European Neuropsychopharmacology. 2021:46:39–48. https://doi.org/10.1016/j.euroneuro.2021.03.019.

8. Jaywant A., Vanderlind W.M., Alexopoulos G.S., Fridman C.B., Perlis R.H., Gunning F.M. Frequency and profile of objective cognitive deficits in hospitalized patients recovering from COVID-19. Neuropsychopharmacology. 2021:46(13):2235–2240. https://doi.org/10.1038/s41386-021-00978-8.

9. Politi L.S., Salsano E., Grimaldi M. Magnetic Resonance Imaging Alteration of the Brain in a Patient With Coronavirus Disease 2019 (COVID-19) and Anosmia. JAMA Neurol. 2020;77(8):1028–1029. https://doi.org/10.1001/jamaneurol.2020.2125.

10. Moein S.T., Hashemian S.M.R., Mansourafshar B., Khorram-Tousi A., Tabarsi P., Doty R.L. Smell dysfunction: a biomarker for COVID-19. Int Forum of Allergy Rhinol. 2020:10(8):944–950. https://doi.org/10.1002/alr.22587.

11. Lechien J.R., Chiesa-Estomba C.M., De Siati D.R., Horoi M., Le Bon S.D., Rodriguez A. et al. Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study. Eur Arch Otorhinolaryngol. 2020:277(8):2251–2261. https://doi.org/10.1007/s00405-020-05965-1.

12. Bagheri S.H.R., Asghari A.M., Farhadi M., Shamshiri A.R., Kabir A., Kamrva S.K. et al. Coincidence of COVID-19 epidemic and olfactory dysfunction outbreak in Iran. Med J Islam Repub Iran. 2020:34:62. Available at: https://pubmed.ncbi.nlm.nih.gov/32974228/.

13. Suzuki M., Saito K., Min W.-P., Vladau C., Toida K., Itoh H., Murakami S. Identification of viruses in patients with postviral olfactory dysfunction. Laryngoscope. 2007:117(2):272–277. https://doi.org/10.1097/01.mlg.0000249922.37381.1e.

14. Gane S.B., Kelly C., Hopkins C. Isolated sudden onset anosmia in COVID-19 infection. A novel syndrome? Rhinology. 2020:1:58(3):299–301. https://doi.org/10.4193/Rhin20.114.

15. Rocke J., Hopkins C., Philpott C., Kumar B.N. Is loss of sense of smell as a diagnostic marker in COVID-19: A Systematic Review and Meta-analysis. Clin Otolaryngol. 2020;45(6):914–922. https://doi.org/10.22541/au.158757120.03114031.

16. van Riel D., Verdijk R., Kuiken T. The olfactory nerve: a shortcut for influenza and other viral diseases into the central nervous system. J Pathol. 2015:235(2):277–287. https://doi.org/10.1002/path.4461.

17. Vaira L.A., Salzano G., Deiana G., De Riu G. Anosmia and ageusia: common findings in COVID-19 patients. Laryngoscope. 2020:130(7):1787–1787. https://doi.org/10.1002/lary.28692.

18. Крюков А.И., Казакова А.А., Гехт А.Б. Нарушение обоняния у больных COVID-19: механизмы и клиническое значение. Вестник оториноларингологии. 2020:85(5):93–97. https://doi.org/10.17116/otorino20208505193.

19. Сhurnin I., Qazi J., Fermin C.R., Wilson J.H., Payne S.C., Mattos J.L. Association between olfactory and gustatory dysfunction and cognition in older adults. Am J Rhinol Allergy. 2019:33(2):170–177. https://doi.org/10.1177/1945892418824451.

20. Dintica C.S., Marseglia A., Rizzuto D., Wang R., Seubert J., Arfanakis K. et al. Impaired olfaction is associated with cognitive decline and neurodegeneration in the brain. Neurology. 2019:92(7):e700–e709. https://doi.org/10.1212/WNL.0000000000006919.

21. Pirker-Keesa A., Platho-Elwischgera K., Hafnera S., Redlichc K., Baumgartnera C. Hyposmia Is Associated with Reduced Cognitive Function in COVID-19: First Preliminary Results. Dement Geriatr Cogn Disord. 2021:50(1):68–73. https://doi.org/10.1159/000515575.

22. Lavi E., Cong L. Type I astrocytes and microglia induce a cytokine response in an encephalitic murine coronavirus infection. Exp Mol Pathol. 2020:115:104474. https://doi.org/10.1016/j.yexmp.2020.104474.

23. Zhou H., Lu S., Chen J., Wei N., Wang D., Lyu H. et al. The landscape of cognitive function in recovered COVID-19 patients. J Psychiatr Res. 2020:129:98–102. https://doi.org/10.1016/j.jpsychires.2020.06.022.

24. Herrmann J., Mori V., Bates J.H.T., Suki B. Modeling lung perfusion abnormalities to explain early COVID-19 hypoxemia. Nat Commun. 2020:11(1):4883. https://doi.org/10.1038/s41467-020-18672-6.

25. Akoumianaki E., Vaporidi K., Bolaki M., Georgopoulos D. Happy or Silent Hypoxia in COVID-19-A Misnomer Born in the Pandemic Era. Front Physiol. 2021:12:745634. https://doi.org/10.3389/fphys.2021.745634.

26. Nation D.A., Sweeney M.D., Montagne A., Sagare A.P., D’Orazio L.M., Pachicano M. et al. Blood-brain barrier breakdown is an early biomarker of human cognitive dysfunction. Nat Med. 2019:25(2):270–276. https://doi.org/10.1038/s41591-018-0297-y.

27. Zetterberg H., Schott J.M. Biomarkers for Alzheimer’s disease beyond amyloid and tau. Nat Med. 2019:25(2):201–203. https://doi.org/10.1038/s41591-019-0348-z.

28. Montagne A., Nation D.A., Sagare A.P., Barisano G., Sweeney M.D., Chakhoyan A. et al. APOE4 leads to blood-brain barrier dysfunction predicting cognitive decline. Nature. 2020:581(7806):71–76. https://doi.org/10.1038/s41586-020-2247-3.

29. Zhang L., Zhou L., Bao L., Liu J., Zhu H., Lv Q. et al. SARS-CoV-2 crosses the blood–brain barrier accompanied with basement membrane disruption without tight junctions alteration. Signal Transduct Target Ther. 2021:6(1):337. https://doi.org/10.1038/s41392-021-00719-9.

30. Krasemann S., Haferkamp U., Pfefferle S., Woo M.S., Heinrich F., Schweizer M. et al. The blood-brain barrier is dysregulated in COVID-19 and serves as a CNS entry route for SARS-CoV-2. Stem Cell Reports. 2022:17(2):307–320. https://doi.org/10.1016/j.stemcr.2021.12.011.

31. Sweeney M.D., Montagne A., Sagare A.P., Nation D.A., Schneider L.S., Chui H.C. et al. Vascular dysfunction – The disregarded partner of Alzheimer’s disease. Alzheimers Dement. 2019:15(1):158–167. https://doi.org/10.1016/j.jalz.2018.07.222.

32. Blazhenets G., Schröter N., Bormann T., Thurow J., Wagner D., Frings L. et al. Slow but evident recovery from neocortical dysfunction and cognitive impairment in a series of chronic COVID-19 patients. J Nucl Med. 2021:62(7):910–915. https://doi.org/10.2967/jnumed.121.262128.

33. Hosp J.A., Dressing A., Blazhenets G., Bormann T., Rau A., Schwabenland M. et al. Cognitive impairment and altered cerebral glucose metabolism in the subacute stage of COVID-19. Brain. 2021:144(4):1263–1276. https://doi.org/10.1093/brain/awab009.

34. Dressing A., Bormann T., Blazhenets G., Schroeter N., Walter L.I., Thurow J. et al. Neuropsychological profiles and cerebral glucose metabolism in neurocognitive Long COVID-syndrome. J Nucl Med. 2021:63(5):121.262677. https://doi.org/10.2967/jnumed.121.262677.

35. Ceban F., Ling S., Lui L.M.W., Lee Y., Gill H., Teopiz K.M. et al. Fatigue and cognitive impairment in Post-COVID-19 Syndrome: A systematic review and meta-analysis. Brain Behav Immun. 2022:101:93–135. https://doi.org/10.1016/j.bbi.2021.12.020.